Repro Med Systems logo
Repro Med Systems KRMD
$ 5.36 -1.65%

Quarterly report 2025-Q3
added 11-12-2025

report update icon

Repro Med Systems Financial Statements 2011-2026 | KRMD

Annual Financial Statements Repro Med Systems

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

96.7 M 179 M 133 M 169 M 240 M 58.3 M 16.1 M 11.4 M 15.1 M 7.15 M 7.92 M 8.39 M 6.09 M

Shares

45.6 M 45 M 44.4 M 41.9 M 38.8 M 38.1 M 37.8 M 38 M 37.6 M 36.7 M 36 M 34.3 M 36.2 M

Historical Prices

2.12 3.98 3 6.02 6.53 1.65 1.25 0.5 0.55 0.47 0.219 0.23 0.26

Net Income

-13.7 M -8.66 M -4.56 M -1.18 M 564 K 911 K -535 K 783 K 753 K 703 K 726 K 816 K 704 K

Revenue

28.5 M 27.9 M 23.5 M 24.2 M 23.2 M 17.4 M 12.3 M 12.2 M 11.2 M 8.7 M 7.76 M 6.39 M 4.92 M

Cost of Revenue

11.8 M 12.5 M 9.72 M 9.24 M 8.31 M 6.54 M 5.17 M - - - - - -

Gross Profit

16.7 M 15.4 M 13.8 M 14.9 M 14.9 M 10.8 M 7.57 M 7.6 M 6.69 M 5.31 M 4.94 M 4.14 M 3.26 M

Operating Income

-10.3 M -10.8 M -7.03 M -1.25 M 586 K 1.16 M 1.24 M 1.18 M 1.15 M 1.01 M 1.06 M 1.29 M 1.19 M

Interest Expense

561 K 146 K 13.1 K 42.4 K 80.7 K 28.1 K 1.89 K 3.41 K 512 4.55 K 28.3 K 31.5 K 36.4 K

EBITDA

-9.4 M -10.2 M -6.57 M -776 K 4.34 M 1.47 M -436 K 1.45 M 1.43 M 1.24 M 1.25 M 1.39 M 1.26 M

Operating Expenses

27 M 26.1 M 20.8 M 16.2 M 10.9 M 9.65 M 8.31 M 6.42 M 5.54 M 4.3 M 3.88 M 2.85 M 2.07 M

General and Administrative Expenses

20.4 M 20.6 M 17.9 M 12 M 9.77 M 9.1 M 7.77 M 5.94 M 4.79 M 3.85 M 3.54 M 2.66 M -

All numbers in USD currency

Quarterly Income Statement Repro Med Systems

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

46.3 M 46.2 M 46 M 46 M 45.9 M 45.8 M 45.7 M 45.6 M 45.6 M 45.6 M 45.5 M 45.4 M 45 M 44.9 M 44.7 M 44.6 M 44.3 M 44.5 M 44 M 43.3 M 43.9 M 40.4 M 39.7 M 39.5 M 39 M 38.4 M 38.2 M 38.2 M 38.2 M 38.1 M 38 M 38 M 37.9 M 37.8 M 37.8 M 37.7 M 37.8 M 38 M 38 M 38 M 38 M 38 M 38 M 38.1 M 37.5 M 37.2 M 36.7 M 36.7 M 36.7 M 36.7 M 36.7 M 36.6 M 35.8 M 35.4 M 35.2 M 38.6 M 37.3 M 36.7 M 34.3 M

Net Income

-778 K -207 K -1.17 M - -1.58 M -989 K -1.94 M - -1.37 M -2.5 M -2.41 M - -1.23 M -2.92 M -2.54 M - -1.09 M -1.12 M -1.28 M - 249 K -1.08 M 449 K - 652 K 78.2 K -85.4 K - 387 K 476 K 403 K - 266 K 148 K 127 K -104 K -153 K -320 K - 168 K 438 K 271 K - 92.7 K 454 K 361 K - 162 K 326 K 164 K - 55.5 K 497 K 441 K - 182 K 498 K 118 K -

Revenue

10.4 M 10.2 M 9.64 M - 8.18 M 8.43 M 8.2 M - 7 M 6.94 M 7.39 M - 7.76 M 6.55 M 6.24 M - 6.04 M 5.53 M 5.43 M - 6.08 M 7.71 M 6.33 M - 6.62 M 5.35 M 4.97 M - 4.55 M 4.5 M 4.03 M - 3.85 M 3.83 M 3.64 M 3.19 M 3.22 M 2.8 M - 3.14 M 8.94 M 5.8 M - 2.66 M 7.8 M 5.14 M - 2.18 M 6.06 M 3.88 M - 2.07 M 5.77 M 3.7 M - 1.5 M 4.36 M 1.36 M -

Cost of Revenue

4.14 M 3.72 M 3.59 M - 2.99 M 2.95 M 3.09 M - 2.66 M 3.05 M 3.25 M - 3.44 M 3.2 M 2.62 M - 2.54 M 2.32 M 2.2 M - 2.14 M 2.8 M 2.54 M - 2.23 M 1.87 M 1.93 M - 1.66 M 1.76 M 1.57 M - 1.47 M 1.53 M 1.54 M - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

6.26 M 6.48 M 6.05 M - 5.19 M 5.48 M 5.1 M - 4.34 M 3.89 M 4.15 M - 4.32 M 3.35 M 3.62 M - 3.5 M 3.21 M 3.23 M - 3.94 M 4.91 M 3.79 M - 4.38 M 3.48 M 3.05 M - 2.89 M 2.74 M 2.47 M - 2.38 M 2.3 M 2.1 M 2.06 M 2.03 M 1.79 M - 2.11 M 5.63 M 3.52 M - 1.58 M 4.74 M 3.16 M - - - - - - - - - - - - -

Operating Income

-868 K -313 K -1.25 M - -1.7 M -1.19 M -1.96 M - -1.79 M -3.22 M -3.06 M - -1.53 M -3.61 M -3.13 M - -1.32 M -1.38 M -2.21 M - 359 K -1.03 M 583 K - 824 K 35.9 K -115 K - 483 K 617 K 501 K - 392 K 190 K 206 K -112 K -228 K -461 K - 290 K 718 K 428 K - 134 K 695 K 560 K - 241 K 501 K 261 K - 87.4 K 776 K 688 K - 226 K 737 K 179 K -

Interest Expense

3.21 K 79 K 73.2 K - 113 K 214 K 37.2 K - 135 K 131 K 126 K - 42.5 K 3.57 K -1.46 K - -2.84 K 9.95 K 9.77 K - 9.66 K -5 K 19 K - 23.4 K 18.2 K 17.5 K - 6.97 K 5.5 K 615 - 361 421 1.64 K 454 262 752 - 929 3.06 K 2.13 K - - 512 512 - - 4.55 K 4.55 K - 7.1 K 21.5 K 14.4 K - 8.2 K 24.1 K 7.82 K -

EBITDA

-663 K -103 K -1.03 M - -1.48 M -974 K -1.73 M - -1.58 M -3.01 M -2.84 M - -1.37 M -3.49 M -3.02 M - -1.21 M -1.26 M -2.1 M - 474 K -937 K 670 K - 907 K 122 K -31.4 K - 561 K 693 K 576 K - 470 K 267 K 281 K -29.2 K -157 K -388 K - 359 K 922 K 563 K - 206 K 897 K 691 K - 299 K 672 K 373 K - 139 K 910 K 772 K - 253 K 810 K 203 K -

Operating Expenses

7.13 M 6.79 M 7.29 M - 6.89 M 6.67 M 7.06 M - 6.13 M 7.11 M 7.2 M - 5.85 M 6.96 M 6.75 M - 4.82 M 4.59 M 5.45 M - 3.58 M 5.94 M 3.21 M - 3.56 M 3.44 M 3.16 M - 2.41 M 2.12 M 1.96 M - 1.99 M 2.11 M 1.9 M 2.18 M 2.26 M 2.25 M - 1.82 M 4.92 M 3.1 M - 1.45 M 4.05 M 2.6 M - - - - - - - - - - - - -

General and Administrative Expenses

5.99 M 5.38 M 5.96 M - 5.13 M 5.32 M 5.36 M - 4.62 M 5.3 M 5.43 M - 4.83 M 5.53 M 5.49 M - 3.9 M 4.09 M 4.99 M - 3.08 M 3.2 M 2.86 M - 2.44 M 2.05 M 2.48 M - 1.92 M 2.02 M 1.88 M - 1.89 M 2.01 M 1.78 M 2.03 M 2.11 M 2.12 M - 1.7 M 4.57 M 2.87 M - 1.26 M 3.44 M 2.18 M - 976 K 2.89 M 1.91 M - 1.11 M 2.66 M 1.55 M - 632 K 1.88 M 656 K -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Repro Med Systems KRMD
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Repro Med Systems plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Medical instruments industry

Issuer Price % 24h Market Cap Country
Atrion Corporation Atrion Corporation
ATRI
- - $ 810 M usaUSA
Baxter International Baxter International
BAX
$ 19.92 0.94 % $ 10.2 B usaUSA
Luminex Corporation Luminex Corporation
LMNX
- - $ 1.75 B usaUSA
Akers Biosciences, Inc. Akers Biosciences, Inc.
AKER
- -9.52 % $ 20.6 M usaUSA
Antares Pharma, Inc. Antares Pharma, Inc.
ATRS
- - $ 955 M usaUSA
Cantel Medical Corp. Cantel Medical Corp.
CMD
- -1.18 % $ 3.4 B usaUSA
CRH Medical Corporation CRH Medical Corporation
CRHM
- - $ 282 M usaUSA
Hill-Rom Holdings, Inc. Hill-Rom Holdings, Inc.
HRC
- -0.05 % $ 10.3 B usaUSA
Varian Medical Systems, Inc. Varian Medical Systems, Inc.
VAR
- -0.02 % $ 16.3 B usaUSA
OraSure Technologies OraSure Technologies
OSUR
$ 2.74 -1.79 % $ 204 M usaUSA
Ekso Bionics Holdings Ekso Bionics Holdings
EKSO
$ 8.65 3.1 % $ 174 M usaUSA
Alcon Alcon
ALC
$ 80.83 -0.37 % $ 40.4 B schweizSchweiz
AtriCure AtriCure
ATRC
$ 36.3 -1.76 % $ 1.7 B usaUSA
Haemonetics Corporation Haemonetics Corporation
HAE
$ 65.68 -0.42 % $ 3.31 B usaUSA
electroCore electroCore
ECOR
$ 6.88 -3.1 % $ 37.9 K usaUSA
AngioDynamics AngioDynamics
ANGO
$ 10.13 1.5 % $ 414 M usaUSA
ICU Medical ICU Medical
ICUI
$ 149.56 -0.31 % $ 3.65 B usaUSA
InfuSystem Holdings InfuSystem Holdings
INFU
$ 8.1 0.56 % $ 167 M usaUSA
STERIS plc STERIS plc
STE
$ 260.7 -0.36 % $ 25.7 B usaUSA
The Cooper Companies The Cooper Companies
COO
$ 80.7 0.41 % $ 16.1 B usaUSA
Masimo Corporation Masimo Corporation
MASI
$ 134.15 -1.54 % $ 7.15 B usaUSA
Harvard Bioscience Harvard Bioscience
HBIO
$ 0.49 -8.67 % $ 20.8 M usaUSA
Glaukos Corporation Glaukos Corporation
GKOS
$ 117.26 -1.52 % $ 5.68 B usaUSA
Merit Medical Systems Merit Medical Systems
MMSI
$ 80.09 -0.19 % $ 4.66 B usaUSA
Isoray Isoray
ISR
- 0.03 % $ 108 M usaUSA
iRhythm Technologies iRhythm Technologies
IRTC
$ 148.9 -0.06 % $ 4.65 B usaUSA
LeMaitre Vascular LeMaitre Vascular
LMAT
$ 84.46 0.72 % $ 1.9 B usaUSA
Intuitive Surgical Intuitive Surgical
ISRG
$ 503.83 -0.73 % $ 179 B usaUSA
NeuroMetrix NeuroMetrix
NURO
- 5.05 % $ 9.02 M usaUSA
Utah Medical Products Utah Medical Products
UTMD
$ 60.61 -1.69 % $ 220 M usaUSA
Microbot Medical Microbot Medical
MBOT
$ 1.82 -2.15 % $ 18.6 M israelIsrael
Nephros Nephros
NEPH
$ 4.4 0.23 % $ 45.7 M usaUSA
Milestone Scientific Milestone Scientific
MLSS
$ 0.3 -1.38 % $ 23.9 M usaUSA
Envista Holdings Corporation Envista Holdings Corporation
NVST
$ 23.08 -1.33 % $ 3.97 B usaUSA
Pro-Dex Pro-Dex
PDEX
$ 37.95 -3.69 % $ 125 M usaUSA
Predictive Oncology Predictive Oncology
POAI
- - $ 31.1 M usaUSA
Pulse Biosciences Pulse Biosciences
PLSE
$ 13.88 1.91 % $ 667 M usaUSA
Becton, Dickinson and Company Becton, Dickinson and Company
BDX
$ 201.3 0.11 % $ 57.9 B usaUSA
Repligen Corporation Repligen Corporation
RGEN
$ 152.02 -2.78 % $ 8.47 M usaUSA
ResMed ResMed
RMD
$ 250.46 -2.78 % $ 36.6 B usaUSA
BioLife Solutions BioLife Solutions
BLFS
$ 21.94 -2.85 % $ 1.01 B usaUSA
Stereotaxis Stereotaxis
STXS
$ 2.24 -3.86 % $ 181 M usaUSA
Retractable Technologies Retractable Technologies
RVP
$ 0.69 -2.01 % $ 20.7 M usaUSA
STAAR Surgical Company STAAR Surgical Company
STAA
$ 18.74 -1.06 % $ 921 M usaUSA
Teleflex Incorporated Teleflex Incorporated
TFX
$ 105.09 -0.37 % $ 4.92 B usaUSA
West Pharmaceutical Services West Pharmaceutical Services
WST
$ 225.53 -3.06 % $ 16.5 B usaUSA
DENTSPLY SIRONA DENTSPLY SIRONA
XRAY
$ 12.32 0.37 % $ 2.5 B usaUSA